Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Carlyle Group Inc (CG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Carlyle Group Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.46 (market cap $29.60B), while Carlyle Group Inc trades at $48.07 (market cap $17.23B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Carlyle Group Inc pays a 2.9% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CG | |
|---|---|---|
Market Cap | $29.60B | $17.23B |
Sector | Health | Financials |
52-Week High | $491.22 | $69.35 |
52-Week Low | $205.48 | $40.52 |
Enterprise Value | $27.56B | — |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Carlyle Group (CG) trades at $47.87, up 0.15% today, with a bullish technical signal and a consensus analyst price target of $59.14. Recent Q2 2026 earnings beat estimates, with EPS of $1.07 versus $0.91 expected, while revenue trends show volatility from $3.4B in 2024 to $3.2B in 2025. The stock is supported by strong institutional interest and dividend payments of $0.35 per share.
The outlook is positive with analyst buy ratings at 54%, but risks include declining net income margins and negative operating cash flows. Investment opportunity lies in valuation upside to the price target, though investors should monitor earnings consistency and macroeconomic impacts on asset management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →
